Abstract 2270P
Background
Pancreatic Adenocarcinoma (PAAD) is a highly fatal disease and often associated with a poor prognosis. The development of diabetes mellitus (DM) is an important risk factor. There have been studies exploring markers or prognostic models that affect the prognosis of patients with pancreatic cancer, but there are few studies on pancreatic cancer-associated diabetes mellitus (PCDM) patients.
Methods
The differentially expressed genes (DEGs) between DM and non-DM were detected and selected to build model. PCDM patients were randomly divided into training (70%) and test cohort (30%). Then the univariate COX was performed to screen OS associated genes (p < 0.05) in the training cohort. The LASSO-penalized COX regression and ten-fold cross validation were used to train and select models. The risk score was calculated and verified in both training and test cohort. GSVA, ESTIMATEScore, CIBERSORT and ssGSEA were used to compare the tumor microenvironment (TME). Moreover, the value of genes used in the model was detected on single cell level.
Results
Totally 197 patients (including 60 with DM) were enrolled, 23 genes from DEGs were related to the OS of PCDM patients in the training cohort, and 10 genes were selected to construct the risk model. The risk score for each subject was calculated as follow: risk score=0.434*ACACA+0.119*ATG7+0.373*DEFB123+0.135*FSTL3-0.168*NIPSNAP3B-0.069*RASSF1+0.225*RBPJ+0.364*SLC35F2-0.168*SLC37A1-0.145*ZC3H12D. The C-index was 0.83 in the training cohort (hazard ratio [HR] = 7.61, p < 0.001) and 0.76 in the test cohort (HR = 3.22, p = 0.015). According to the median value -0.054, PCDM patients were split into different risk groups, and patients in the low-risk group showed more enriched T cell related pathways (60 vs 1), higher ImmuneScore (p < 0.001), and more CD8 positive T cell infiltration (CIBERSORT: p < 0.001; ssGSEA: p < 0.001). We calculated the score of genes used in the model in single cells. Malignant cells with the highest score (top 10%) had enhanced activities of angiogenesis.
Conclusions
The prognostic model showed potential value in predicting the OS of patients with PCDM. Patients with low-risk score had a hotter TME and might benefit from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2305P - Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
Presenter: Sejin Kim
Session: Poster session 08
2306P - How TAILORx changed treatment allocation based on 21-gene recurrence score in the daily clinic: A single center retrospective analysis
Presenter: Elena Chiru
Session: Poster session 08
2307P - Loss of CYP2D6 activity sensitizes liver cancer cells to chemotherapy
Presenter: Natallia Rameika
Session: Poster session 08
2308P - CyPep-1 reprograms the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors
Presenter: Bassam Janji
Session: Poster session 08
2309P - High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment
Presenter: Laura Dillon
Session: Poster session 08
2310P - Oxygen nano-bubbles attenuate hypoxia-induced tumour malignancy in tumour xenograft models
Presenter: Kumari Bhavya
Session: Poster session 08
2311P - Population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2βγR and CTLA4
Presenter: Dongwoo Chae
Session: Poster session 08
2312P - SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Presenter: Annamaria Bonelli
Session: Poster session 08
2313P - APOBEC mutagenesis and macrophage infiltration in cancer
Presenter: Andrea Gazzo
Session: Poster session 08
2314P - Quality and safety of research biopsies (RB) in oncology clinical trials
Presenter: Paolo Nuciforo
Session: Poster session 08